Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 19Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Neoplasm Metastasis 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer 2Small Cell Lung Carcinoma 1Recurrence 1Prostate Adenocarcinoma 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Follicular 1Colorectal Neoplasms 1Castrate Sensitive Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Bulbo-Spinal Atrophy, X-Linked 1Bites and Stings 1Advanced Prostate Cancer 1Adenocarcinoma 1

Interventions

enzalutamide 1darolutamide 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bulbo-Spinal Atrophy, X-Linked × enzalutamide × 30 days × Clear all
NCT03437941 2026-05-15

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Corcept Therapeutics

Phase 1/2 Terminated
39 enrolled 43 charts
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡